Gastroenterologist: "22 Years of Training Didn't Teach Me What Ozempic and Wegovy Were Doing to My Patients' Stomachs. 40 Minutes With a Motility Researcher Did."

There is a quiet crisis affecting millions of women on GLP-1 medications. It is stealing 9 to 18 months of normal gastric function from women who do not know there is a clock running. It is convincing them, one specialist appointment at a time, that the suppression is permanent — when in fact it is reversible only if they act inside the window. The very condition American doctors call "GLP-1 constipation that will regulate on its own" is actually a reversible motility suppression — provided the window is still open.

I am talking about something most general practitioners and many GIs miss completely.

This is not gradual gastric aging. The cause is not menopause-related, and it is not the slow constipation you read about for older women. What you are dealing with is sudden-onset motility suppression triggered by a medication that mutes the vagal signal at the same time it suppresses appetite.

The suppression happens fast. It looks permanent — and most American GIs will tell you it is. They are wrong. The signal is reversible, but only inside the window.

The Patient Who Made Me Furious At My Own Profession

I am Dr. Rebecca Marsh. I have practiced gastroenterology for 22 years, specializing in motility disorders.

Three months ago, a woman walked into my clinic on a self-referral. Her name was Patricia Donovan. She was 61. She had lost 52 pounds on Mounjaro between June and April of last year.

She handed me her phone. Open on the screen was a spreadsheet. Columns: date, time, attempt, result. Eleven days of "no" in the result column.

"My GP said constipation is normal on GLP-1s," Patricia told me. "She told me to give it time. That was four months ago. I am four months from the day she said give it time."

That is when it hit me. This was not "give it time" constipation. It was something specific. I had now seen it dozens of times in the past 18 months — almost always in women who had lost weight on Mounjaro, Ozempic, Wegovy, or Zepbound.

I spent that weekend going through my patient records from the past two years. What I found made me furious at my own profession.

Twenty-three women with an identical clinical pattern, all on GLP-1 medications, all given the same sentence by their general practitioner or primary GI: "increase your fiber, drink more water, try Miralax."

Fiber does not reach where the problem is. Miralax does not either. And we have been missing the obvious answer for two years.

Your Stomach's Motility Suppression, Compressed Into Months

I pulled the Japanese motility research on GLP-1-induced gastroparesis. I cross-referenced it with the vagal adaptation papers from the European motility consortium. I compared both to the timelines of when each of those twenty-three women had first noticed the change.

The pattern was unmistakable.

What American gastroenterologists are calling "GLP-1 constipation" is not the lower-bowel sluggishness they have been trained to diagnose. It is gastric motility suppression — the same biological event Japanese motility specialists treat in chronic gastroparesis patients, but compressed into a shorter timeline and triggered by a medication instead of nerve damage.

When you take a GLP-1, two things happen in your digestive system at the same time:

First, the medication slows gastric emptying. This is the mechanism that delays your satiety signal. It is how the medication suppresses appetite. Food sits in your stomach hours longer than it should. The food does not get processed — it ferments. Hydrogen sulfide gas builds up in the stomach. That is the source of the sulfur burps.

Second, the medication suppresses the vagal signal that tells your stomach when to contract. Your vagus nerve normally fires every 90 to 120 minutes to push contents through. On a GLP-1, that signal weakens. Over months, your stomach adapts to the suppressed signal. Contractions become less frequent. The force weakens with every month that passes. By month eight, the rhythm is unreliable.

Your stomach muscle does not waste away. It goes dormant. It stops generating the contraction pattern that normal digestion requires.

The result is what your GP sees in the lower bowel and treats as constipation. But the suppression is happening earlier in the digestive tract — in the stomach — at a location no colon-targeting laxative can reach.

Why "Give It Time" Costs You The Window

This is the part that made me furious.

From approximately month 4 on a GLP-1 medication — when major weight loss begins — you have approximately 9 to 18 months where your vagal motility signaling can still be supported back to normal function. The signal is suppressed. It is not extinguished. But it is not unlimited time either.

After that window, the suppression patterns become entrenched. Your stomach has adapted to the low-function state for long enough that even reducing the dose — or stopping the medication entirely — does not restore normal motility. Published research on post-GLP-1 gastroparesis shows symptoms persisting for 6 to 12 months after discontinuation in patients who never addressed the underlying suppression while still on the drug.

This means the constipation you are tolerating right now can outlast the medication that caused it.

Most of the women in my clinic are 11 to 16 months into this window. Most have spent every single one of those months on Miralax, fiber gummies, and supplements that cannot reach where the suppression is happening.

Every month a woman waits for her constipation to "regulate on its own" is a month closer to permanent damage. Her general practitioner has no idea this clock is running. Her prescribing doctor weighed her every month for a year and never once mentioned it.

Gastroenterologists Are Treating Suppressed Motility Like Regular Constipation

I tested every solution American gastroenterologists typically recommend. They are all designed for one condition. That condition is not the one GLP-1 patients have.

Miralax (polyethylene glycol). Pulls water into the colon to soften what is sitting in the lower bowel. The blockage is not in the colon. The food is stalled in the stomach. Adding water to the colon does nothing to move what is stuck four feet earlier in the digestive tract.

Dulcolax and senna. Force contractions in the colon. The colon is not where the blockage sits — stimulating it produces nothing because nothing has arrived there.

Magnesium citrate. Same osmotic mechanism as Miralax, working in the colon — and the same wrong location.

Fiber gummies and psyllium powder. Add bulk for the colon to push through. When the stomach cannot push food through, adding bulk to a stalled system makes the gas worse and the heaviness more pronounced. This is the single piece of advice that makes the condition worse.

Smooth Move tea and prune juice. Lower-intestine stimulation. Same wrong location, same useless approach for this specific suppression.

Standard probiotic capsules. Designed to colonize the lower bowel. The bacterial fermentation problem is happening in the stomach because food is sitting there too long. Adding bacteria does not fix the dwell time. It makes the fermentation worse.

What GI specialists are not telling you is this: treating GLP-1-induced motility suppression requires the exact opposite approach from treating regular constipation.

Regular constipation needs colon stimulation.

GLP-1 suppression requires the opposite — reactivation of the vagal signal that the medication has muted.

That is when I remembered something Japanese motility specialists have been using for over a decade.

Japanese Motility Specialists Use a Different Approach Entirely

Gastric motility reactivation is not complicated. It is just unfamiliar to American GIs trained on laxative protocols.

Three distinct requirements have to work together. Miss one and the other two do not matter.

REQUIREMENT 1: VAGAL SIGNAL SUPPORT.

The compound with the strongest evidence in Japanese motility research is apigenin — a flavonoid found in high concentration in celery. Apigenin supports vagal tone and the cholinergic signaling that triggers gastric contractions. It does not override the GLP-1. It supports the same signal the medication is suppressing — which means the stomach can begin contracting again without compromising the appetite suppression that is giving you the weight loss.

REQUIREMENT 2: GAS NEUTRALIZATION.

Once food has been fermenting in the stomach for weeks, hydrogen sulfide has been accumulating faster than the body can clear it. Reactivating motility alone does not address the gas that has already formed. Sodium copper chlorophyllin — a concentrated form of chlorophyll — binds directly to hydrogen sulfide molecules and neutralizes them at the source. This is the documented gas-neutralization compound in clinical gastroenterology literature. It does not mask the smell — it disarms the molecule that creates it.

REQUIREMENT 3: LOWER-BOWEL FLOW SUPPORT.

Weeks of stalled gastric motility mean the small intestine and colon have been dehydrated and densely packed. Once the stomach starts working again, what is sitting in the small intestine and colon needs to soften and clear without adding bulk. Insoluble fiber makes the problem worse. The documented compound is low-bulk soluble prebiotic fiber — gel-forming, draws moisture in, softens what is dehydrated without adding volume to a system that already cannot move quickly.

This is not new science. Japanese gastroenterologists have used these protocols for over a decade. American supplement companies have not invested in proper formulation because basic laxatives are dramatically more profitable to manufacture and sell at retail.

Then I found one company that broke ranks.

The Only Formulation I Have Found That Meets All Three Requirements

For two years, I had been recommending these compounds individually to my patients. Apigenin from one supplier. Chlorophyllin drops from a second. A specific prebiotic fiber from a third. I could not recommend anything on the retail market because every "GLP-1 digestive support" product I tested failed at least one requirement.

Most used ginger extract for motility — which acts on the upper esophagus, not gastric contractions. Others had chlorophyll but no signal support. The rest had insoluble fiber blends that would have made the situation worse.

In 2024, a small company released a formulation called Motilli. I tested it in my own clinic for four months before I would speak about it publicly.

Standardized celery juice concentrate for apigenin, at the dose used in the Japanese motility studies. Sodium copper chlorophyllin at therapeutic concentration. Low-bulk soluble prebiotic fiber matched to the dehydrated-bowel protocol I had been recommending by hand for two years.

It was the first retail product I had ever seen — at any price point — that met all three clinical requirements simultaneously.

19 of 22 Patients Showed Measurable Motility Reversal

I started a formal observation in my clinic. The criteria were strict: women aged 50-70, on Mounjaro, Wegovy, Ozempic, or Zepbound for at least six months, currently 6-18 months from start of major weight loss, with at least three failed conventional treatments on file.

Each woman received Motilli on a specific protocol — two gummies daily, for 90 days. No other interventions. No diet changes. No other products.

After 30 days, I re-measured gastric motility using bowel-movement frequency tracking, validated bloating-severity self-report, and daily sulfur-burp count.

Nineteen out of twenty-two showed measurable improvement. Not stabilized — improved. Average bowel-movement frequency rose from once every 5.2 days to once every 1.4 days. Sulfur-burp counts fell by 78 percent on average. The three women who showed only partial reversal had all been past month 17 from start of GLP-1 — their windows were already mostly closed.

Patricia Donovan texted me on her week-three follow-up: "I went this morning. On my own. No Miralax. No laxatives. I have not done that since I started Mounjaro. I almost cried."

Another patient came back to my office in tears at her week-ten check-in. "My husband asked if I had changed my medication. He said I seem like myself again. He did not know I had been gone."

What Makes Motilli Different From Everything Else

After four months of clinical observation in my own practice and direct conversations with the formulators, here is what makes Motilli different from everything else you have already tried:

• 1
  Three Compounds, Not One Apigenin from celery juice concentrate, sodium copper chlorophyllin, and low-bulk soluble prebiotic fiber. The only retail product I have found that meets all three motility requirements at clinically meaningful doses.
• 2
  Gummy Format Designed for GLP-1 Stomachs GLP-1 patients often cannot tolerate pills. The gummy format avoids the nausea-triggering swallowing reflex and is gentler on a stomach that is already suppressed.
• 3
  Apigenin at Clinical-Study Concentration Standardized celery juice concentrate matched to the dose used in the published Japanese motility research, not a token sprinkle of "celery extract" for label appeal.
• 4
  Designed for Motility Suppression, Not Constipation Every American "constipation supplement" is formulated to stimulate the colon. Motilli is formulated to reactivate the stomach. Different condition altogether — different formulation required.
• 5
  Insoluble-Fiber-Free Most fiber supplements add bulk to a system that already cannot move quickly. Motilli uses low-bulk soluble prebiotic fiber that softens what is stuck without adding volume.
• 6
  Specifically Tracked in Post-GLP-1 Patients 19 of 22 women in our clinic observation who experienced motility suppression after rapid weight loss on Mounjaro, Wegovy, Ozempic, or Zepbound showed measurable reversal within 90 days of consistent twice-daily use.

Where to Find Motilli

If you want to reactivate gastric motility while you are still inside your window — without giving up your GLP-1, without accepting "this is just how it is now," without watching another month of your reversal window close — then you need to act inside that window.

Motilli is sold only through the manufacturer at getmotilli.com. Not Amazon. Not GNC. Not any third-party retailer — partly to control batch quality, partly because production cannot scale to general retail at the dose concentrations the formulation requires.

I just learned that a major women's health publication is preparing a feature on Motilli for their 400,000+ readers next month. With Google searches for "constipation after Ozempic" up over 800 percent year over year, I expect that feature to clear out the next batch within days.

Right now, women who visit the link below can still get Motilli at a significant reader discount — but only while remaining inventory lasts. If you leave without checking availability, there is no guarantee you will still be inside your reversal window when stock returns.

According to the Japanese motility research I have been reviewing for over a decade, women experiencing GLP-1-induced gastric motility suppression face:

• A 9 to 18 month reversal window from the onset of major weight loss
• Adaptive vagal suppression that persists 6-12 months after discontinuation if untreated during the window
• Exponentially harder recovery for every additional month of delay

That is a lot of lost time. And a lot of preventable damage.

You have a closing window. Accepting "this is just how GLP-1s are" costs you that window. Wait long enough and the suppression outlasts the medication that caused it.

Motilli provides clinical-grade gastric motility support without procedures, without injections, without giving up your weight loss. For less than the cost of a single specialist consultation (Patricia's first co-pay alone was $185 for an appointment that offered no solution), you can give your stomach its chance at full recovery while the window is still open.

The choice is yours: keep accepting "give it time," or take action while your reversal window is still open.

I wish someone had told Patricia Donovan about her window before she wasted four months on laxatives that could not reach where the suppression was. Don't make the same mistake.